Synthetic nanocarriers as a new paradigm

Nanomedicine

Volumn 9, Issue 15, 2014, Pages 2259-2262

  Shiekh, Farooq A ^a  

^a Department of Basic Medical Sciences Avalon University School of Medicine   (Netherlands)

Author keywords

nanocarriers; nanomedicine; nanoparticles; nanotherapeutics; synthetic biology

Indexed keywords

NANOCARRIER; DRUG CARRIER; NANOMATERIAL;

DRUG DELIVERY SYSTEM; HUMAN; NANOENGINEERING; NANOFABRICATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NOTE; SYNTHETIC BIOLOGY;

DRUG CARRIERS; NANOSTRUCTURES;

EID: 84912079547     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.163     Document Type: Note

References (53)

1. Benner SA, Sismour AM. Synthetic biology. Nat. Rev. Genet. 6(7), 533-543 (2005).
2. Endy D. Foundations for engineering biology. Nature 438(7067), 449-453 (2005).
3. Drubin DA, Way JC, Silver PA. Designing biological systems. Genes Dev. 21(3), 242-254 (2007).
4. Chen YY, Smolke CD. From DNA to targeted therapeutics: bringing synthetic biology to the clinic. Sci. Transl. Med. 3(106), 106ps42 (2011).
5. Church GM, Elowitz MB, Smolke CD, Voigt CA, Weiss R. Realizing the potential of synthetic biology. Nat. Rev. Mol. Cell Biol. 15(4), 289-294 (2014).
6. Paddon CJ, Westfall PJ, Pitera DJ et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496(7446), 528-532 (2013).
7. Cameron DE, Bashor CJ, Collins JJ. A brief history of synthetic biology. Nat. Rev. Microbiol. 12(5), 381-390 (2014).
8. Reardon S. Visions of synthetic biology. Science 333(216), 1242-1243 (2011).
9. Nelson B. Synthetic biology: cultural divide. Nature 509(7499), 152-154 (2014).
10. ter Meulen V. Time to settle the synthetic controversy. Nature 509(7499), 135 (2014).
11. Carr PA, Church GM. Genome engineering. Nat. Biotechnol. 27(12), 1151-1162 (2009).
12. Redden H, Morse N, Alper HS. The synthetic biology toolbox for tuning gene expression in yeast. FEMS Yeast Res. doi:10.11111567-1364.12188 (2014) (Epub ahead of print).
13. Chaput JC. Replicating an expanded genetic alphabet in cells. Chembiochem 15(13), 1869-1871 (2014).
14. Nielsen J, Fussenegger M, Keasling J et al. Engineering synergy in biotechnology. Nat. Chem. Biol. 10(5), 319-322 (2014).
15. Pinheiro VB, Holliger P. Towards XNA nanotechnology: new materials from synthetic genetic polymers. Trends Biotechnol. 32(6), 321-328 (2014).
16. Silver PA, Way JC, Arnold FH, Meyerowitz JT. Synthetic biology: engineering explored. Nature 509(7499), 166-167 (2014).
17. Lienert F, Lohmueller JJ, Garg A, Silver PA. Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat. Rev. Mol. Cell Biol. 15(2), 95-107 (2014).
18. Auslander D, Auslander S, Charpin-El HamriG et al. A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device. Mol. Cell 55(3), 397-408 (2014).
19. Heng BC, Aubel D, Fussenegger M. G protein-coupled receptors revisited: therapeutic applications inspired by synthetic biology. Annu. Rev. Pharmacol. Toxicol. 54, 227-249 (2014).
20. Sun X, Vilar S, Tatonetti NP. High-throughput methods for combinatorial drug discovery. Sci. Transl. Med. 5(205), 205rv1 (2013).
21. Silver PA, Way JC, Arnold FH, Meyerowitz JT. Synthetic biology: engineering explored. Nature 509(7499), 166-167 (2014).
22. Way JC, Collins JJ, Keasling JD, Silver PA. Integrating biological redesign: where synthetic biology came from and where it needs to go. Cell 157(1), 151-161 (2014).
23. Paddon CJ, Keasling JD. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat. Rev. Microbiol. 12(5), 355-367 (2014).
24. Ye H, Fussenegger M. Synthetic therapeutic gene circuits in mammalian cells. FEBS Lett. 588(15), 2537-2544 (2014).
25. Nielsen J, Fussenegger M, Keasling J et al. Engineering synergy in biotechnology. Nat. Chem. Biol. 10(5), 319-322 (2014).
26. Weber W, Fussenegger M. Emerging biomedical applications of synthetic biology. Nat. Rev. Genet. 13(1), 21-35 (2012).
27. Weber W, Fussenegger M. The impact of synthetic biology on drug discovery. Drug Discov. Today 14(19-20), 956-963 (2009).
28. Putnam D. Design and development of effective siRNA delivery vehicles. Proc. Natl Acad. Sci. USA 111(11), 3903-3904 (2014).
29. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 341(6151), 1192-1198 (2013).
30. Collins JJ, Maxon M, Ellington A, Fussenegger M, Weiss R, Sauro H. Synthetic biology: how best to build a cell. Nature 509(7499), 155-157 (2014).
31. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 287(5460), 1969-1973 (2000).
32. Galdzicki M, Clancy KP, Oberortner E et al. The Synthetic Biology Open Language (SBOL) provides a community standard for communicating designs in synthetic biology. Nat. Biotechnol. 32(6), 545-550 (2014).
33. Copeland WB, Bartley BA, Chandran D et al. Computational tools for metabolic engineering. Metab. Eng. 14(3), 270-280 (2012).
34. Pum D, Sleytr UB. Reassembly of S-layer proteins. Nanotechnology 25(31), 312001 (2014).
35. Price R, Poursaid A, Ghandehari H. Controlled release from recombinant polymers. J. Control. Release 190, 304-313 (2014).
36. Khalil AS, Collins JJ. Synthetic biology: applications come of age. Nat. Rev. Genet. 11(5), 367-379 (2010).
37. Lu TK, Khalil AS, Collins JJ. Next-generation synthetic gene networks. Nat. Biotechnol. 27(12), 1139-1150 (2009).
38. O'Donoghue P, Ling J, Wang YS, Soll D. Upgrading protein synthesis for synthetic biology. Nat. Chem. Biol. 9(10), 594-598 (2013).
39. Thyer R, Ellefson J. Synthetic biology: new letters for life's alphabet. Nature 509(7500), 291-292 (2014).
40. Huang X, Pallaoro A, Braun GB et al. Modular plasmonic nanocarriers for efficient and targeted delivery of cancer-therapeutic siRNA. Nano Lett. 14(4), 2046-2051 (2014).
41. Service RF. Materials and biology. Nanotechnology takes aim at cancer. Science 310(5751), 1132-1134 (2005).
42. Bourzac K. Nanotechnology: carrying drugs. Nature 491(7425), S58-S60 (2012).
43. Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 7(11), 9571-9584 (2013).
44. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291), 1067-1070 (2010).
45. Lord PG, Papoian T. Genomics and drug toxicity. Science 306(5697), 575 (2004).
46. Shiekh FA. Personalized nanomedicine: future medicine for cancer treatment. Int. J. Nanomedicine 8, 201-202 (2013).
47. Shiekh FA. Targeted nanotherapeutics in cancer. Int. J. Nanomedicine 26, 1627-1628 (2014).
48. Zoroddu MA, Medici S, Ledda A, Nurchi VM, Lachowicz JI, Peana M. Toxicity of nanoparticles. Curr. Med. Chem. 21(33), 3837-3853 (2014).
49. Shiekh FA. Blood-brain barrier: a real obstacle for therapeutics. Int. J. Nanomedicine 7, 4065-4066 (2012).
50. Burello E, Worth A. Computational nanotoxicology: predicting toxicity of nanoparticles. Nat. Nanotechnol. 6(3), 138-139 (2011).
51. Brophy JA, Voigt CA. Principles of genetic circuit design. Nat. Methods 11(15), 508-520 (2014).
52. Shopsowitz KE, Roh YH, Deng ZJ, Morton SW, Hammond PT. RNAi-microsponges form through self-assembly of the organic and inorganic products of transcription. Small 10(8), 1623-1633 (2014).
53. Morton SW, Lee MJ, Deng ZJ et al. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 7(325), ra44 (2014).